Toxic shock syndrome toxin-1

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Retrieved on: 
Tuesday, October 31, 2023

WEXFORD, Pa., Oct. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego. 

Key Points: 
  • SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
  • Further, in another leukemia model targeting the CD20 antigen, SNAP-CAR T cells showed significant inhibition of tumor growth.
  • "While still early in its development, we continue to see vast potential for the SNAP-CAR platform for treating both liquid and solid tumor malignancies."
  • "The data being presented at SITC 2023 encapsulates the groundbreaking research being conducted at the University of Pittsburgh, which demonstrates the potential of SNAP-CAR T-cells to reduce tumor burden and tumor growth in numerous cancers, including HER2-expressing and CD20-expressing cancers," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 17, 2023

“Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.

Key Points: 
  • “Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.
  • As per the latest data cut-off of April 4, 2023, ACTengine® IMA203 TCR-T monotherapy Cohort A showed a 67% confirmed objective response rate (cORR) in an interim clinical update announced on May 2, 2023.
  • Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME-targeted TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023.
  • TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA2) to the Paul-Ehrlich-Institute (PEI) in April 2023.

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023

WALTHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Key Points: 
  • Revenue for the second quarter ended June 30, 2023, was $3.1 million, compared to $4.1 million for the second quarter ended June 30, 2022 (2022 Quarter).
  • Research and development expenses for the second quarter ended June 30, 2023, were $21.2 million, compared to $14.5 million for the 2022 Quarter.
  • General and administrative expenses for the second quarter ended June 30, 2023, were $6.5 million, compared to $4.8 million for the 2022 Quarter.
  • For the second quarter ended June 30, 2023, TScan Therapeutics reported a net loss of $24.0 million, compared to a net loss of $15.1 million for the 2022 Quarter.

CoImmune Announces Publication of Preclinical Data Demonstrating Efficacy and Specificity of CAR-CIK Cells in Acute Myeloid Leukemia

Retrieved on: 
Wednesday, July 5, 2023

DURHAM, N.C., July 5, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the publication of preclinical data demonstrating that a strategy based on the company's proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML). The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.

Key Points: 
  • The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.
  • The dual strategy demonstrated powerful antitumor efficacy against AML targets without any relevant toxicity on hematopoietic stem and progenitor cells (HSPCs) and endothelial cells.
  • Specifically, the researchers found:
    CD123 and/or CD33 knockout impairs leukemia growth by modulating multiple cancer pathways in a model of NPM1-mutated AML.
  • Low affinity CAR-CIK cells preserve antileukemic efficacy in vitro and improve antitumor control in vivo.

Orbit Discovery and Evergreen Discovery Collaborate to Discover Peptides for Targeting Radiopharmaceuticals

Retrieved on: 
Monday, April 3, 2023

Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

Key Points: 
  • Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.
  • The agreement covers activities ranging from designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties.
  • The radiopharmaceuticals market is rapidly expanding with the development of a variety of targeting moieties.
  • Peptides are increasingly seen as a valuable delivery option, as their specificity, stability and rapid clearance has the potential to reduce off-target toxicities.

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Retrieved on: 
Tuesday, March 21, 2023

In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.

Key Points: 
  • In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
  • This allows Immatics to shorten the turnaround time and to provide the cell therapy product candidate to patients faster.
  • In October 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
  • Immatics successfully completed an underwritten public offering in October 2022, raising approximately $110 million before deducting underwriting discount and offering expenses.